Aurora kinases as targets in drug-resistant neuroblastoma cells.
Aurora kinase inhibitors displayed activity in pre-clinical neuroblastoma models. Here, we studied the effects of the pan-aurora kinase inhibitor tozasertib (VX680, MK-0457) and the aurora kinase inhibitor alisertib (MLN8237) that shows some specificity for aurora kinase A over aurora kinase B in a...
Main Authors: | Martin Michaelis, Florian Selt, Florian Rothweiler, Nadine Löschmann, Benedikt Nüsse, Wilhelm G Dirks, Richard Zehner, Jindrich Cinatl |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4182628?pdf=render |
Similar Items
-
Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
by: Martin Michaelis, et al.
Published: (2020-03-01) -
Intact-Cell MALDI-ToF Mass Spectrometry for the Authentication of Drug-Adapted Cancer Cell Lines
by: Jane F. Povey, et al.
Published: (2019-10-01) -
The pan-Aurora kinase inhibitor tozasertib as a repurposed drug for Mycn-amplified neuroblastoma
by: Chun-Li Hou, et al.
Published: (2016) -
BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells
by: Chandan Kanta Das, et al.
Published: (2018-03-01) -
Karanjin interferes with ABCB1, ABCC1, and ABCG2
by: Martin Michaelis, et al.
Published: (2014-03-01)